Treatment of hepatocellular carcinoma and the exacerbation of liver function

  • Authors:
    • Hiroshi Okano
    • Katsuya Shiraki
    • Hidekazu Inoue
    • Masatoshi Deguchi
    • Kazushi Sugimoto
    • Takahisa Sakai
    • Shigeru Ohmori
    • Kazumoto Murata
    • Takeshi Nakano
    • Koichiro Yamakado
    • Kan Takeda
  • View Affiliations

  • Published online on: December 1, 2001     https://doi.org/10.3892/ijo.19.6.1279
  • Pages: 1279-1282
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We performed interventional treatments on 50 patients with hepatocellular carcinoma (HCC) and analyzed the relationship between these treatments and the exacerbation of liver function after treatment. The different treatments included transcatheter arterial embolization (TAE), percutaneous ethanol injection therapy (PEIT), selective segmental sclerotherapy (SSS), combined TAE and PEIT, or transcatheter arterial chemo-injection (TAI). Thirteen patients showed an exacerbation of liver function after treatment. The laboratory data on admission, showed the lower levels of serum albumin and cholinesterase in this group. In comparison to patients who did not show any exacerbation of liver function, these 13 patients had undergone combined TAE and PEIT. An analysis of cases after TAE and PEIT treatment revealed that the time from TAE to PEIT was shorter in the exacerbation group than in the non-exacerbation group, however, there was no significant difference in the amount of injected ethanol between the two groups. It is assumed that the values of albumin and cholinesterase before treatment, or the period from TAE to PEIT are related to liver failure after treatment. Combining TAE and PEIT treatment may be effective for HCC, however, we should pay special attention to liver failure after treatment.

Related Articles

Journal Cover

December 2001
Volume 19 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Okano H, Shiraki K, Inoue H, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Murata K, Nakano T, Yamakado K, Yamakado K, et al: Treatment of hepatocellular carcinoma and the exacerbation of liver function. Int J Oncol 19: 1279-1282, 2001.
APA
Okano, H., Shiraki, K., Inoue, H., Deguchi, M., Sugimoto, K., Sakai, T. ... Takeda, K. (2001). Treatment of hepatocellular carcinoma and the exacerbation of liver function. International Journal of Oncology, 19, 1279-1282. https://doi.org/10.3892/ijo.19.6.1279
MLA
Okano, H., Shiraki, K., Inoue, H., Deguchi, M., Sugimoto, K., Sakai, T., Ohmori, S., Murata, K., Nakano, T., Yamakado, K., Takeda, K."Treatment of hepatocellular carcinoma and the exacerbation of liver function". International Journal of Oncology 19.6 (2001): 1279-1282.
Chicago
Okano, H., Shiraki, K., Inoue, H., Deguchi, M., Sugimoto, K., Sakai, T., Ohmori, S., Murata, K., Nakano, T., Yamakado, K., Takeda, K."Treatment of hepatocellular carcinoma and the exacerbation of liver function". International Journal of Oncology 19, no. 6 (2001): 1279-1282. https://doi.org/10.3892/ijo.19.6.1279